Zealand Pharma A/S

Zealand Pharma is a biotechnology company. Co. is engaged in the discovery development and commercialization of peptide-based medicines. Co.'s pipeline comprises two implementation areas: Cardio-metabolic diseases and Other indications. The Cardio-metabolic diseases area includes medicines for diabetes and obesity treatment, such as Lyxumia (Lixisenatide), Lyxumia/Lantus, ZP2929 and Danegaptide. The Other indications area are ZP1848, Elsiglutide and ZP1480 (ABT-719) drugs for inflammatory bowel disease, chemotherapy-induced diarrhea and acute kidney injury treatment.
  • TickerZLDPF
  • ISINDK0060257814
  • ExchangePink OTC Markets
  • SectorPharmaceuticals & Biotechnology
  • CountryUnited States

Analysts

Eric Le Berrigaud

ZEALAND: The right CEO, at the right time, to convey new messages and prepare for the next phase | BUY | DKK180 vs. DKK143 (+31%)

ZEALAND - BUY | DKK180 vs. DKK143 (+31%) The right CEO, at the right time, to convey new messages and prepare for the next phase First very positive impression from first meeting with new CEO Glepaglutide should do better than Gattex Dasiglucagon: a multi-dimensional discussion to conduct

Oussema Denguir ...
  • Pierre Corby

Zealand Pharma : Substantial newsflow for the next twelve months

>Q1 2019 results - Zealand Pharma yesterday afternoon reported its financial results for Q1 2019. No sales recorded over the period (after the sale of the rights for Soliqua and Lyxumia to Royalty Pharma last September), the operating loss widened to DKK 136m (vs -DKK 88m in Q1 2018) underscoring the decline in revenues and the rise in opex (R&D +36% to DKK 121m; +80% SG&A to DKK 14.5m) which reflects the progress of the development of the various molecules in its pip...

Oussema Denguir ...
  • Pierre Corby

Zealand Pharma : Du newsflow d’importance pour les 12 prochains mois

>Résultats T1 2019 - Zealand Pharma a publié hier après-midi ses résultats au titre du T1 2019. Sans CA enregistré sur la période (après la cession des droits de Soliqua et de Lyxumia à Royalty Pharma en septembre dernier), la perte opérationnelle se creuse à 136 MDKK (vs -88 MDKK au T1 2018) soulignant à la fois la baisse des revenus ainsi que l’augmentation des Opex (R&D +36% à 121 MDKK ; +80% SG&A à 14.5 MDKK) qui traduit l’avancement du développement des différent...

Eric Le Berrigaud

ZEALAND: Technology-validating deal with Alexion | BUY | DKK143 vs. DKK149

ZEALAND - BUY | DKK143 vs. DKK149 (+26%) Technology-validating deal with Alexion Alexion gets rights to up to four peptide targets FY 2018 released last week required some adjustments Our new FV is DKK143

Oussema Denguir ...
  • Pierre Corby

Zealand Pharma : Publication contained no surprises, abundant newsflow in 2019

>DKK 1.15bn at end-2018 - Zealand Pharma yesterday evening reported its 2018 results, sales, as expected, fell by 72% to DKK 38m following the sale of the licensing rights for Soliqua and Lyxumia to Royalty Pharma in June 2018. Opex increased by 29% to DKK 481m (in line with expectations), reflecting the progress of the company's various clinical programmes for an operating profit of DKK 652.4m, boosted by the one-off sale of rights to its partnership with Sanofi (DKK...

1 director sold

A director at Zealand Pharma As sold 10,000 shares at 138.110DKK and the significance rating of the trade was 60/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names of b...

Aurelien Sivignon ...
  • Fehmi Ben Naamane
  • Jean Sassus
  • Jean-François Granjon
  • Matthias Desmarais
  • Oussema Denguir
  • Pierre Corby
  • Steven Gould

ODDO BHF Small & MIDCAP MORNING NEWS - 05/17/2019

...

Aurelien Sivignon ...
  • Fehmi Ben Naamane
  • Jean Sassus
  • Jean-François Granjon
  • Matthias Desmarais
  • Oussema Denguir
  • Pierre Corby
  • Steven Gould

ODDO BHF Small & MIDCAP MORNING NEWS - 17/05/2019

...

Christophe Chaput ...
  • Christophe-Raphaël Ganet
  • Fatma Agnès Hamdani
  • Geoffroy Michalet
  • Hela Zarrouk
  • Jean-François Granjon
  • Jeremy Garnier
  • Oussema Denguir
  • Pierre Corby

ODDO BHF Small & MIDCAP MORNING NEWS - 03/08/2019 Date Performance since listing Date Performance since listing

Sixt Leasing, an independent player in the German vehicle leasing and fleet management market, stands out for its strong momentum in the online retail and fleet management segments and its capacity to handle the diesel risk effectively. These strengths should pave the way for buoyant growth over the coming years (2018-2021e CAGR of +8% for revenue and 15% for pre-tax profit) and a rerating of the stock (target price € 18.1, i.e. 34% upside). We are initiating coverage of the stock wit...

Christophe Chaput ...
  • Christophe-Raphaël Ganet
  • Fatma Agnès Hamdani
  • Geoffroy Michalet
  • Hela Zarrouk
  • Jean-François Granjon
  • Jeremy Garnier
  • Oussema Denguir
  • Pierre Corby

ODDO BHF Small & MIDCAP MORNING NEWS - 08/03/2019

Sixt Leasing, acteur indépendant du marché allemand du leasing de véhicules et de gestion de flottes, se distingue par sa forte dynamique sur les segments Online Retail et Fleet Management, ainsi que par sa capacité à gérer efficacement le risque diesel. Ces atouts se traduiront par une croissance soutenue sur les prochaines années (TMVA18-21e CA : +8% ; RCAI : 15%) et par une revalorisation du titre (OC 18.1 €, soit un potentiel de 34%). Nous initions la couverture avec une opinion A...

Aurelien Sivignon ...
  • Emmanuel Matot
  • Hana Maalej
  • Harold De Decker
  • Jeremy Garnier
  • Jerôme Bodin
  • Oussema Denguir
  • Pierre Corby
  • Valentin Pernet

ODDO BHF Small & MIDCAP MORNING NEWS - 19/09/2018

...

ZEALAND PHARMA AS reduced its risk exposure resulting in an upgrade to Slightly Positive

ZEALAND PHARMA AS (DK), a company active in the Biotechnology industry, reduced its market risk and raised its general evaluation. The independent financial analyst theScreener awarded an improved star rating to the company, which now shows 2 out of 4 possible stars; its market behaviour has improved and can be considered as defensive. theScreener believes that this new assessment merits an overall rating upgrade to Slightly Positive. As of the analysis date March 22, 2019, the closing price was DKK 118.60 and its potential was estimated at DKK 124.53.

ValuEngine Rating and Forecast Report for ZEAL

ValuEngine Rating and Forecast Report for ZEAL

ValuEngine Rating and Forecast Report for ZEAL

ValuEngine Rating and Forecast Report for ZEAL

ValuEngine Rating and Forecast Report for ZEAL

ValuEngine Rating and Forecast Report for ZEAL

ValuEngine Rating and Forecast Report for ZEAL

ValuEngine Rating and Forecast Report for ZEAL

ResearchPool Subscriptions

Get the most out of your insights

Get in touch